|
Physiomics PLC - oncology consultancy based in Oxford, England - Wins third contract by an existing client, Numab Therapeutics. Says it will use its PKPD modelling capabilities to support the translation of pre-clinical to clinical data with a focus on dose selection. The project is expected to be completed between now and the end of 2022.
Chief Executive Officer Jim Millen says: ‘We are pleased to continue our collaboration with Numab and to have been selected to continue to support the development of their multispecific antibody-based therapeutics.’
Numab Therapeutics is a Switzerland-based biotechnology firm.
Current stock price: 2.13 pence
12-month change: down 66%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
